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Abstract
Objective—Concerns about including pregnant women in research have led to a dearth of 
evidence to guide safe and effective treatment and prevention of HIV in pregnancy. To better 
understand why these evidence gaps persist and inform guidance for responsible inclusion of 
pregnant women in the HIV research agenda, we aimed to learn what HIV experts perceive as 
barriers and constraints to conducting this research.
Methods—We conducted a series of group and one-on-one consultations with 62 HIV 
investigators and clinicians to elicit their views and experiences conducting HIV research 
involving pregnant women. Thematic analysis was used to identify priorities and perceived 
barriers to HIV research with pregnant women.
Results—Experts discussed a breadth of needed research, including safety, efficacy and 
appropriate dosing of: newer ARVs for pregnant women, emerging preventive strategies, and 
treatment for co-infections. Challenges to conducting research on pregnancy and HIV included 
ethical concerns, such as how to weigh risks and benefits in pregnancy; legal concerns, such as 
restrictive interpretations of current regulations and liability issues; financial and professional 
disincentives, including misaligned funder priorities and fear of reputational damage; and 
analytical and logistical complexities, such as challenges recruiting and retaining pregnant women 
to sufficiently power analyses.
Conclusions—Investigators face numerous challenges to conducting needed HIV research with 
pregnant women. Advancing such research will require clearer guidance regarding ethical and 
legal uncertainties; incentives that encourage rather than discourage investigators to undertake 
such research; and a commitment to earlier development of safety and efficacy data through 
creative trial designs.
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There is an urgent need for effective HIV prevention and treatment during pregnancy. An 
estimated 1.5 million women living with HIV give birth each year, and among the 2 million 
people each year who acquire HIV, about 1 million are women of reproductive age [1, 2]. 
Moreover, accumulating evidence indicates that women face an increased risk of HIV 
acquisition during pregnancy [3, 4].
Despite this enormous need, and the tremendous scientific advancements in prevention and 
treatment of HIV, there are major gaps in understanding how best to address the health needs 
of pregnant women living with or at risk for HIV. While the evidence for prevention of 
mother-to-child transmission (PMTCT) is robust, health outcomes focus nearly exclusively 
on the fetus. Little is known about which antiretrovirals or biomedical prophylaxis methods 
are safest and most effective in pregnancy [5, 6, 7]; while recent Southern African guidelines 
list pregnancy as a contraindication to pre-exposure prophylaxis (PrEP), WHO guidelines 
indicate “PreP can be used in pregnancy” alongside calls for further study [8, 9]. Data are 
similarly lacking for treatment of HIV co-infections like tuberculosis (TB) during 
pregnancy, despite the major contribution of multidrug-resistant TB to perinatal morbidity 
and mortality [10, 11, 12].
These gaps are part of a broader problem afflicting the management of illness during 
pregnancy [13, 14, 15, 16, 17]. Especially for HIV, the failure to build an adequate evidence 
base widens the health outcomes gap between pregnant women and other populations, 
contravening the commitment to “make sure no one is left behind” in the ambitious fast-
track plan to end the epidemic by 2030 [18].
In 2013, we launched PHASES (Pregnancy and HIV/AIDS: Seeking Equitable Study), a 
project aimed at developing ethically responsible, action-guiding recommendations for 
advancing research to address these evidence gaps. To create guidance responsive to the 
needs, priorities, and experiences of HIV investigators whose work addresses issues relevant 
to pregnant women, we have been conducting engagement meetings and one-on-one 
conversations with experts in HIV research. Through consultations with more than 62 HIV 
experts working across multiple areas of investigation and global contexts, we solicited 
perspectives on the most significant barriers – perceived or real – to the conduct of HIV 
research in pregnancy. These experts were largely based at U.S. institutions, though 7 
consultations were conducted in South Africa and of 62 experts consulted, nearly half 
conducted their research solely in international settings (predominantly in sub-Saharan 
Africa). To further explore both global and country-specific perspectives on this area, our 
project has ongoing consultations in South Africa, Botswana and Malawi.
Roadblocks to Research
In our discussions, HIV investigators and clinicians endorsed a pressing need for more 
evidence to guide effective and safe treatment and prevention of HIV in pregnant women. 
Mirroring gaps discussed in the literature [19, 20, 21], they identified areas of need 
including pregnancy safety and dosing information for newer ARVs; optimal treatment 
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following PMTCT; safety and efficacy of emerging preventive strategies, such as 
microbicides, vaginal rings, oral pre-exposure prophylaxis (PrEP), and vaccines; treatment 
for HIV co-infections, including tuberculosis and malaria; as well as guidance for 
diagnostics. One commonly cited example was efavirenz, for which a lack of safety data in 
pregnancy resulted in reticence to use the drug, leading not only to limited treatment options 
for pregnant women, but also potentially poorer health outcomes given regimen changes and 
adverse effects associated with alternative ARVs. Within this context of limited evidence 
regarding pregnant women and HIV, these experts identified a wide range of barriers to 
gathering needed data.
Ethical Concerns: Risks, benefits and a “Catch-22” problem
HIV experts discussed ethical complexities of clinical research with pregnant women. They 
noted challenges in weighing potential risks and benefits of the research for the woman and 
the fetus, especially when the interests of one seemingly do not align with the other. 
Assessing relative risks and benefits across the two parties is further complicated by the 
dismal state of the evidence, giving rise to what one expert called a “Catch-22” dilemma: 
limited safety data on HIV-related drugs in pregnancy sparks concerns about unknown 
potential maternal-fetal exposure risks; this leads to reluctance to study pregnant women, in 
turn perpetuating the lack of safety data that could inform next steps for research. Some 
investigators also raised questions about obtaining meaningful consent, including but not 
limited to questions about the degree to which it is ethically appropriate or necessary to 
involve the biological father in the consent process.
Legal Concerns: Implications of confusing and complex regulations
Investigators frequently discussed how difficulties interpreting research regulations can 
impede research with pregnant women. Many discussed the U.S. regulations specific to the 
protection of pregnant women, human fetuses, and neonates known as “Subpart B” [22]. 
Despite Subpart B’s statement that research with pregnant women is permissible, many 
investigators had experiences leading them to believe that oversight officials do not want 
pregnant women enrolled: often no justification was requested by oversight officials or 
required by IRB processes to exclude pregnant women from studies, and investigators noted 
that the general presumption was that pregnant women were ineligible, reinforcing the 
erroneous view that research with pregnant women is impermissible under current 
regulations. Several investigators described instances where research was thwarted by 
extremely cautious interpretations of “minimal risk” – a regulatory limit on risk for studies 
holding no prospect of direct benefit to the woman or her fetus. One investigator, aiming to 
delineate pharmacokinetic parameters of novel ARVs shared that, in her experience, 
regulators and some IRBs have held that a single dose of medication in pregnancy, even 
given at a fraction of the dose used clinically and in the third trimester, constitutes more than 
minimal risk.
Fear that IRBs would not approve studies discouraged some investigators from even 
attempting to include pregnant women in HIV research. This fear was exacerbated in multi-
site trials, where approval from multiple IRBs was required.
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Finally, some raised concerns about potential individual or institutional legal liability should 
the offspring be harmed during a study. Liability was also cited as a disincentive for 
collecting pregnancy-specific data that could be used for labeling, since this could open a 
pharmaceutical company to post-marketing liability should adverse effects be noted over 
time. This was particularly salient given the current emphasis on effects of in-utero 
exposures on long-term health outcomes of children.
Financial and professional disincentives
Many investigators discussed financial considerations as a source of reticence to include 
pregnant women. Some commented that, in their experience, pharmaceutical companies do 
not perceive pregnant women as a population likely to yield large returns on R&D 
investment. Furthermore, some noted that these studies can cost more to conduct, requiring 
longer-term follow up, provision of ancillary antenatal care, and potential legal costs linked 
to aforementioned liability concerns.
We also heard opinions that public funding agencies are biased against studies with pregnant 
women, with some calling these proposals “non-starters.” Many felt that the challenging 
funding climate, characterized by “donor fatigue,” coupled with the professional pressures to 
obtain grants and publish, discouraged them or their colleagues from attempting to include 
pregnant women, particularly when their study questions were not specific to pregnancy. A 
few voiced concerns about safeguarding their professional reputations, remarking that no 
investigator wanted to be perceived as exposing fetuses to harm or risk like the thalidomide 
debacle. In light of this reality, one investigator expressed frustration that the small number 
of HIV researchers interested in pregnancy – even collectively – cannot “beat a big enough 
drum” to be heard by funders or others shaping research priorities.
Analytical and logistical complexities
Investigators explained that including pregnant women in clinical research can be 
logistically challenging and analytically complicated. Data associated with women who are 
or become pregnant during a study must be analyzed separately, reducing sample size and 
statistical power. Additionally, some highlighted challenges in collecting data at fixed time 
points in pregnancy, noting that tracking down participants is difficult even without the 
added pressure of ensuring contact at particular pregnancy intervals. Recruitment can also be 
challenging, particularly when partners are involved in enrollment processes. Some 
researchers described going to great lengths in certain settings for “buy-in” from men to 
recruit pregnant women. Low enrollment also makes it difficult to run subgroup analyses for 
pregnancy-specific information. Loss-to-follow-up post-partum and longer-term was also a 
concern; some noted a common tendency for women to move to areas where they have 
greater family support after giving birth. While some of these challenges are also relevant to 
other populations, they were understood by the experts we interviewed as particularly 
relevant to decisions about whether to conduct research with pregnant women.
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The way forward? Toward a roadmap to navigate the challenges
This long list of challenges may seem discouraging, but there is good news. Our 
consultations suggest that evidence gaps for the HIV response in pregnancy are due neither 
to lack of will among investigators nor their failure to recognize the research and clinical 
needs of pregnant women. Rather, these gaps are largely a function of questions, 
disincentives, and barriers in the wider research environment resulting in patterns of 
resistance and uncertainty. Left unaddressed, they will continue to erode the prospects for a 
much-needed evidence base. While these challenges are significant, they are not 
insurmountable.
Recent history shows that the landscape is navigable. The PMTCT experience reminds us 
that research involving pregnant women can proceed. Moreover, a progressive vanguard of 
studies on preventives and treatments in pregnancy demonstrates what is possible through 
creative trial designs – and persistence [23, 24]. A “road map” clearly identifying when and 
how research with pregnant women can responsibly proceed will help pave the way for more 
successful HIV trials to promote the health of pregnant women and their offspring through 
evidence-based practice.
In developing this “road map,” our consultations point to at least three areas of need. The 
first is clearer guidance for investigators, IRBs, and regulatory agencies on what sorts of 
studies with pregnant women are ethically and legally permissible. These individuals face 
the difficult challenge of making decisions about research in the absence of a broadly 
recognized ethical framework for guiding clinical research in pregnancy [25] and ongoing 
debate about what it would entail [26]. Such guidance will require ethical and legal analysis 
of the conditions for responsible HIV research with pregnant women, informed by academic 
and regulatory experts and legal practitioners, and responsive to the priorities and concerns 
of those who might conduct or participate in needed studies. The guidance would attend to 
such issues as when it is permissible to impose fetal risk, how such risks should be 
interpreted and communicated given uncertainty, and when risks can ethically be traded off 
between woman and fetus. Establishing a clearer sense of ethically responsible research that 
attends to the legal complexities may also bolster investigators’ confidence that studies 
involving pregnant women will be allowed to proceed. This guidance should be accessible 
with practical tools, which might include sample protocols, case examples, and best 
practices for research oversight, including IRB processes that shift the evaluative stance 
from presumed exclusion of pregnant women to explicit discussion of and justification for 
decisions about pregnancy as an inclusion or exclusion criterion.
The second entails aligning incentives to encourage, rather than discourage, investigators to 
undertake this important research. This will necessarily include mobilizing investment in 
pregnancy-relevant research among key funders and building political will among those that 
control or influence the research agenda through focused advocacy efforts. Regulatory 
agencies can also play a significant role in shifting incentives. The recent move by the FDA 
to require study of sex differences in animal studies is a powerful example of what can be 
accomplished by focal regulatory interventions, and could serve as a precursor for policies 
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that would accelerate reproductive toxicity studies for drugs likely to be used by pregnant 
women.
Third is a commitment to generating safety and efficacy data through creative trial designs to 
interrupt the “Catch-22” of fetal risk uncertainty. Exposure registries, opportunistic studies, 
and combined Phase I/II trial designs can help bypass the vexations of “minimal risk” 
determinations – the first two because no additional risk is associated with the research, and 
Phase I/II because they involve prospects of direct benefit, allowing appropriately higher 
permissible risk thresholds. For example, the Microbicide Trials Network EMBRACE study 
(MTN-016) is a prospective observational cohort study of pregnancy outcomes, as well as 
growth parameters, major malformations and drug resistance in infants of women who either 
unintentionally became pregnant while in microbicide or PrEP trials or participated in a 
safety study of a HIV prevention agent during pregnancy [27]. Similarly, the International 
Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network Study 1026s has 
helped characterize pharmacokinetics of newer antiretrovirals among pregnant women (and 
infants) taking medications for clinical indications [28, 29]. IMPAACT 2001, a Phase I/II 
trial, examines the pharmacokinetics, tolerability, and safety of once-weekly rifapentine and 
insoniazid for treatment of latent TB in pregnant women with and without HIV-infection 
[30].
Conclusion
Identifying a clear path forward for HIV research in pregnancy is crucial to the advancement 
of maternal and child health. The evidence garnered from such research is critical to 
identifying appropriate dosing, providing faster access to improved frontline medications, 
reducing reticence to prescribing beneficial interventions, and addressing treatment 
discontinuity.
Over the next three years, PHASES will develop and disseminate concrete, consensus-driven 
guidance for research with pregnant women. This guidance will provide criteria for ethically 
responsible HIV research in pregnancy across a range of risks, benefits, and trade-off 
scenarios; a portfolio of creative study designs and practical strategies that have successfully 
advanced needed research; and recommendations for when in the lifecycle of drug 
development, drug approval, and clinical use pregnant women should be included in studies. 
Importantly, the utility and acceptability of these materials will be vetted by a range of 
stakeholders and experts in HIV and women’s health. We hope this guidance will facilitate 
more successful, efficient, and ethical HIV trials addressing the needs of pregnant women, 
ultimately shifting the research agenda to improve clinical and public health practices for 
pregnant women and their children through the rigorous evidence base they deserve.
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